
WELLlife™ COVID-19 / Influenza A&B Test
For Emergency Use Authorization (EUA) only* | For in vitro diagnostic use WELLlife™ COVID-19 / Influenza A&B Test utilizes advanced immunoassay technology to quickly and accurately differentiate between SARS-CoV-2, influenza A, and influenza B with a single nasal swab. Recommended for rapid diagnostics, this test is an essential tool for timely management of viral infections, supporting swift treatment decisions during the flu season and amidst public health concerns. INTENDED USE: The WELLlife™ COVID-19 / Influenza A&B Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 within the first five (5) days of symptom onset when tested at least twice over three days with at least 48